Ascendis Pharma A/S

SecurityASND / Ascendis Pharma A/S
InstitutionWalleye Capital LLC
Latest Disclosed Ownership37 shares
Latest Disclosed Value $ 8,463
Walleye Capital LLC ownership in ASND / Ascendis Pharma A/S

On May 13, 2026 - Walleye Capital LLC filed a 13F-HR/A form disclosing ownership of 37 shares of Ascendis Pharma A/S (US:ASND) valued at $8,463 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 628 shares of Ascendis Pharma A/S. This represents a change in shares of -94.11% during the quarter. The current value of the position is $8,021 USD.

Walleye Capital LLC has a history of taking positions in derivatives of the underlying security (ASND) in the form of stock options. The firm currently holds call options representing 3,700 of underlying shares valued at $846,301 USD and put options representing 2,600 of underlying shares valued at $594,698 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

ASND / Ascendis Pharma A/S Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F/A-1 ASCENDIS PHARMA A SPONSORED ADR 04351P101 37 -591 -94.11 8 -93.98 0.0000
2026-05-08 2026-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 37 -591 8 0.0000
2026-02-13 2025-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 628 628 134 0.0004
2025-11-14 2025-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 0 -40,403 -100.00 0 -100.00
2025-08-13 2025-06-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 40,403 24,566 155.12 6,974 182.54 0.0271
2025-05-14 2025-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 15,837 15,837 2,468 0.0111
2025-02-13 2024-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 0 -1,014 -100.00 0 -100.00
2024-11-14 2024-09-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 1,014 458 82.37 151 101.33 0.0003
2024-08-14 2024-06-30 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 556 527 1,817.24 76 1,775.00 0.0001
2024-05-15 2024-03-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 29 -1,133 -97.50 4 -97.26 0.0000
2024-02-14 2023-12-31 13F ASCENDIS PHARMA A SPONSORED ADR 04351P101 1,162 1,162 146 0.0003
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-13 2026-03-31 13F/A ASCENDIS PHARMA A SPONSORED ADR Call 3,700 -19.57 846 -13.67 n/a n/a n/a
2026-05-08 2026-03-31 13F ASCENDIS PHARMA A SPONSORED ADR Call 3,700 846 n/a n/a n/a
2026-02-13 2025-12-31 13F ASCENDIS PHARMA A SPONSORED ADR Call 4,600 318.18 981 349.54 n/a n/a n/a
2025-11-14 2025-09-30 13F ASCENDIS PHARMA A SPONSORED ADR Call 1,100 57.14 219 81.67 n/a n/a n/a
2025-08-13 2025-06-30 13F ASCENDIS PHARMA A SPONSORED ADR Call 700 121 n/a n/a n/a
2025-02-13 2024-12-31 13F ASCENDIS PHARMA A SPONSORED ADR Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-11-14 2024-09-30 13F ASCENDIS PHARMA A SPONSORED ADR Call 900 -55.00 134 -50.74 n/a n/a n/a
2024-08-14 2024-06-30 13F ASCENDIS PHARMA A SPONSORED ADR Call 2,000 -33.33 273 -39.96 n/a n/a n/a
2024-05-15 2024-03-31 13F ASCENDIS PHARMA A SPONSORED ADR Call 3,000 400.00 454 504.00 n/a n/a n/a
2024-02-14 2023-12-31 13F ASCENDIS PHARMA A SPONSORED ADR Call 600 -68.42 76 -57.63 n/a n/a n/a
2023-11-21 2023-09-30 13F/A ASCENDIS PHARMA A SPONSORED ADR Call 1,900 -26.92 178 -23.71 n/a n/a n/a
2023-11-14 2023-09-30 13F ASCENDIS PHARMA A SPONSORED ADR Call 1,900 178 n/a n/a n/a
2023-08-14 2023-06-30 13F ASCENDIS PHARMA A SPONSORED ADR Call 2,600 -53.57 232 -61.33 n/a n/a n/a
2023-05-15 2023-03-31 13F ASCENDIS PHARMA A SPONSORED ADR Call 5,600 -13.85 600 -24.34 n/a n/a n/a
2023-02-14 2022-12-31 13F ASCENDIS PHARMA A SPONSORED ADR Call 6,500 96.97 794 132.55 n/a n/a n/a
2022-11-14 2022-09-30 13F ASCENDIS PHARMA A SPONSORED ADR Call 3,300 341 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-13 2026-03-31 13F/A ASCENDIS PHARMA A SPONSORED ADR Put 2,600 -7.14 595 -0.50 n/a n/a n/a
2026-05-08 2026-03-31 13F ASCENDIS PHARMA A SPONSORED ADR Put 2,600 595 n/a n/a n/a
2026-02-13 2025-12-31 13F ASCENDIS PHARMA A SPONSORED ADR Put 2,800 833.33 597 911.86 n/a n/a n/a
2025-11-14 2025-09-30 13F ASCENDIS PHARMA A SPONSORED ADR Put 300 200.00 60 247.06 n/a n/a n/a
2025-08-13 2025-06-30 13F ASCENDIS PHARMA A SPONSORED ADR Put 100 -83.33 17 -81.72 n/a n/a n/a
2025-05-14 2025-03-31 13F ASCENDIS PHARMA A SPONSORED ADR Put 600 94 n/a n/a n/a
2024-11-14 2024-09-30 13F ASCENDIS PHARMA A SPONSORED ADR Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F ASCENDIS PHARMA A SPONSORED ADR Put 1,700 -5.56 232 -15.07 n/a n/a n/a
2024-05-15 2024-03-31 13F ASCENDIS PHARMA A SPONSORED ADR Put 1,800 -28.00 272 -13.38 n/a n/a n/a
2024-02-14 2023-12-31 13F ASCENDIS PHARMA A SPONSORED ADR Put 2,500 -19.35 315 8.28 n/a n/a n/a
2023-11-21 2023-09-30 13F/A ASCENDIS PHARMA A SPONSORED ADR Put 3,100 290 n/a n/a n/a
2023-11-14 2023-09-30 13F ASCENDIS PHARMA A SPONSORED ADR Put 3,100 290 n/a n/a n/a
2023-08-14 2023-06-30 13F ASCENDIS PHARMA A SPONSORED ADR Put 0 -100.00 0 -100.00 n/a n/a n/a
2023-05-15 2023-03-31 13F ASCENDIS PHARMA A SPONSORED ADR Put 4,400 -20.00 472 -29.81 n/a n/a n/a
2023-02-14 2022-12-31 13F ASCENDIS PHARMA A SPONSORED ADR Put 5,500 323.08 672 400.75 n/a n/a n/a
2022-11-14 2022-09-30 13F ASCENDIS PHARMA A SPONSORED ADR Put 1,300 134 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.